Indivina

Medroxyprogesterone acetate, the active ingredient in Indivina, is a combined estrogen‑progestogen presented as an oral tablet for oral use. It is used to replace deficient endogenous hormones, alleviating menopausal symptoms and protecting the endometrium in post‑menopausal women.

GNH USA supplies Indivina as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Indivina is a combined estrogen‑progestogen indicated for conditions related to estrogen deficiency and menopause. - Menopausal symptoms: relief of hot flashes, night sweats, and vaginal atrophy. - Prevention of osteoporosis: helps maintain bone density in post‑menopausal women. - Endometrial protection: reduces risk of estrogen‑induced endometrial hyperplasia when used with estrogen therapy.

Common side effects are generally mild and reversible.

Common Side Effects: - Nausea - Headache - Breast tenderness - Weight gain - Mood changes - Vaginal spotting

Serious or Rare Side Effects: - Venous thromboembolism - Stroke or transient ischemic attack - Liver dysfunction (elevated enzymes, cholestasis) - Severe allergic reaction (anaphylaxis) - Hyperglycemia in diabetic patients

Before initiating therapy, clinicians should evaluate individual risk factors and monitor patients regularly. - Cardiovascular assessment: evaluate history of thromboembolic disease or clotting disorders. - Breast health: perform regular clinical exams and imaging as indicated. - Liver function: monitor enzymes in patients with hepatic impairment. - Bone health: consider baseline bone mineral density testing. - Hormone‑dependent tumors: avoid use in patients with known estrogen‑sensitive cancers. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Drug interactions may alter efficacy or increase risk of adverse events.

Major Interactions (Avoid): - Combined oral contraceptives: additive risk of thromboembolism. - Anticoagulants (e.g., warfarin): potential alteration of anticoagulant effect. - Strong CYP3A4 inducers (e.g., rifampicin): may reduce hormone plasma levels.

Moderate Interactions (Monitor Closely): - Antihypertensives: possible fluid retention may affect blood pressure control. - SSRIs and SNRIs: may increase incidence of mood changes. - Herbal supplements such as St. John’s wort: could decrease hormonal effectiveness. - Antidiabetic agents: monitor glucose as hormones may affect glycemic control.